Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

SGYP 2.88 -0.02 (-0.69%)
price chart
Synergy Pharmaceuticals Drug Fares Well in Phase II Study
We believe more than SP-333, investors focus is most likely to stay on Synergy Pharma's lead candidate, plecanatide. Synergy Pharma is currently evaluating plecanatide in two phase III studies for the treatment of chronic idiopathic constipation (CIC).
Synergy Pharma constipation drug succeeds mid-stage trial  Yahoo News
Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial ...  MarketWatch
Related articles »  
REFILE-Synergy Pharma constipation drug succeeds mid-stage trial
Nov 19 (Reuters) - Synergy Pharmaceuticals Inc said its experimental drug for opioid induced constipation was found safe and effective in a mid-stage trial.
Synergy Pharma (SGYP) Phase 2 Trial of SP-333 Meets Primary Endpoint  StreetInsider.com (subscription)
Related articles »  
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10%
Synergy Pharmaceuticals, Inc. (SGYP - Snapshot Report) was a big mover last session, as the company saw its shares rise 10% on the day.
Related articles »  
Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million ...
Related articles »  
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% - Tale of the Tape
was a big mover last session, as the company saw its shares rise 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up ...
Related articles »  
Synergy Pharmaceuticals Inc. Announces Full Exercise of Over-Allotment Option
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the full exercise of the over-allotment option granted to the initial purchasers to ...
Related articles »  
Synergy Pharmaceuticals Inc (SGYP): Synergy Pharmaceuticals' Upcoming Trial ...
With multiple 2014 catalysts approaching, investor interest should remain strong for Synergy Pharmaceuticals. With positive data thus far, additional promising data could be strong share price movers for the company as additional indications are ...
Synergy Pharma Progresses with Plecanatide  Zacks.com
Related articles »  
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of ...
Related articles »  
Synergy Pharmaceuticals Inc. Announces Private Offering of Convertible Senior ...
NEW YORK, Oct 28, 2014 (BUSINESS WIRE) -- Synergy Pharmaceuticals Inc. SGYP, -0.69% (the �Company�),a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal ...
Related articles »  
Synergy Pharmaceuticals Inc (SGYP), Proteon Therapeutics Inc (PRTO): James ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E. Flynn's Deerfield Management and Peter Kolchinsky's RA Capital Management started new stakes in them lately.
Cantor Fitzgerald Reaffirms Buy Rating for Synergy Pharmaceuticals (SGYP)  sleekmoney
Monday Healthcare Trader's Watch List: AcelRx Pharmaceuticals (ACRX ...  WallStreet Scope
Related articles »